3D Medicines, Inc. (HK:1244) has released an update.
3D Medicines Inc. reports a significant 41.4% drop in revenue for the first half of 2024 compared to the same period in 2023, attributing the decline to intense competition in the PD-1/L1 market. Despite cost-cutting measures leading to reduced expenses in sales and research and development, the company faced a 40% decrease in total comprehensive loss. The financial health of the company shows a 19.8% reduction in cash and bank balances along with other financial assets.
For further insights into HK:1244 stock, check out TipRanks’ Stock Analysis page.
